Non-alcoholic Fatty Liver Disease Clinical Trial
Verified date | September 2017 |
Source | Shiraz University of Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study design to examine performance of trigonella foenum-graecum (TFG) in treatment of non-alcoholic fatty liver disease. Base on inclusion and exclusion criteria, 50 patients select and then randomize into intervention and control groups. Two group use capsules which contain TFG or placebo, respectively.
Status | Completed |
Enrollment | 35 |
Est. completion date | September 2017 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion criteria: - The level of ALT and AST greater than 1.5 and less than 10 times normal level - Ultrasound evidence confirm fatty liver disease; age between 18-70 years old - Negative pregnancy test for women in reproductive age (up to two weeks prior to the study) - Negative for hepatitis B and C - BMI: 18.5 to 40 - Sign the consent form. Exclusion criteria: - History of more than one unit of alcohol consumption (one value for the Spirits (vodka; whiskey) - Wine and Beer are respectively 30-45 cc; 120-150 cc and 360 cc.) - Fatty liver controller medications - Glucose lowering drugs - Cholesterol lowering drugs - Hypotensive drugs - Consumption of vitamin E - Taking coenzyme Q10 - Administration of corticosteroids & glucocorticoids - Thyroxin administration - Administration of drugs that cause fatty liver - Diabetes (type 1 and 2) - History of cancer in the past - Hepatocellular carcinoma - Renal failure (creatinine> 1.5 x ULN) - Chronic pancreatitis - Cirrhosis - Uncontrolled hypertension (above 180 mm Hg systolic blood pressure); heart disease - Autoimmune hepatitis - Primary biliary cirrhosis - Primary sclerosing cholangitis (alkaline phosphatase levels greater than 3 times normal) - Wilson's disease - Alpha-1 antitrypsin deficiency and coronary artery disease - Symptoms of hypothyroidism - Hyperthyroidism - Disorders of the hypothalamic - pituitary - Liver transplantation - Pregnant or lactating women - Those who cannot use contraceptives. |
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Shiraz University of Medical Sciences | Shiraz | Fars |
Lead Sponsor | Collaborator |
---|---|
Shiraz University of Medical Sciences |
Iran, Islamic Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Liver stiffness change | Assessment by Fibroscan | At baseline and 12 weeks after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |